Your browser doesn't support javascript.
loading
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.
Barrows, Stephanie M; Wright, Kelly; Copley-Merriman, Catherine; Kaye, James A; Chioda, Marc; Wiltshire, Robin; Torgersen, Knut Martin; Masters, Elizabeth T.
Afiliación
  • Barrows SM; Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.
  • Wright K; Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.
  • Copley-Merriman C; Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.
  • Kaye JA; Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA.
  • Chioda M; Medical Affairs, Pfizer, Inc., New York, NY, USA.
  • Wiltshire R; Medical Affairs, Pfizer Limited, Walton Oaks, UK.
  • Torgersen KM; Medical Affairs, Pfizer, Inc., Oslo, Norway.
  • Masters ET; Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA.
Lung Cancer (Auckl) ; 10: 11-20, 2019.
Article en En | MEDLINE | ID: mdl-30804692
The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4-89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5-22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Systematic_reviews Idioma: En Revista: Lung Cancer (Auckl) Año: 2019 Tipo del documento: Article Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Systematic_reviews Idioma: En Revista: Lung Cancer (Auckl) Año: 2019 Tipo del documento: Article Pais de publicación: Nueva Zelanda